Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06739759

Ovarian Hyperstimulation Syndrome Prevention

Ovarian hyperstimulation is a very hazardous complication of ICSI

Recruiting

Interested in participating?

Request Info

Key information

Age range

19 year–42 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Algazeerah, Giza, Egypt

Loading trial locations.

About this study

Ovarian hyperstimulation could be mild , moderate , severe or marked

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women with PCOS coming for ICSI

Exclusion criteria

  • Women who donnot have PCOS

Treatment and study plan

Antagonist protocol for IVF

Drug

antagonist protocol with triggering by Decapeptyl

Other names: Antagonist

Modified Agonist protocol for IVF with additive treatments as HCQ

Drug

giving additive drugs to agonist protocolas HCQ

Other names: modified agonist with additives

Primary outcomes

  1. prevention of OHSS

    Time frame: within 3 weeks

    prevention of symptoms of ovarian hyperstimulation syndrome as amount of ascites in litres by US

Study contacts

Contact information is provided by the study sponsor or research team.

Ahmed Elgazzar, MD

CONTACT

[email protected]

01014005959

Mahmoud Alalfy, MD

CONTACT

[email protected]

01002611058

Sponsors and collaborators

Lead sponsor

Aljazeera Hospital

Other

Registry information

Official study title

Prophylaxis Against Ovarian Hyperstimulation Syndrome in PCOS Women

Acronym: OHSS

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Dec 18, 2024
Registry last updated
Dec 18, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.